We therefore provide a grade 1A Recommendation for use of SGLT-2 inhibition in people without DM with an eGFR ≥20 mL/min/1.73m2 and uACR ≥25 mg/mmol, or those with symptomatic heart failure. Here, SLC5A2 is linked to diabetes mellitus.